- AU$30.65m
- AU$24.15m
- AU$4.05m
Brief: Emyria Records FY Net Loss Attributable A$7.3 Mln
Australia's Emyria soars as it gets ethics approval for EMD-RXS Phase 3 trial
Brief: Emyria Says Emyria Receives Ethics Approval For Emd-Rx5 Phase 3 Trial
Brief: Emyria Seeks Trading Halt
Australia Stock Exchange release from EMYRIA : Broker Briefing Presentation
Australia Stock Exchange release from EMYRIA : Emyria to present webinar, March 24th
Australia Stock Exchange release from EMYRIA : Letter to Shareholders - Adjourned General Meeting
Australia Stock Exchange release from EMYRIA : Addendum to Notice of Meeting and Proxy Form
Australia's healthcare firm Emyria jumps on new CBD capsule launch
Australia Stock Exchange release from EMYRIA : PRE_NR Ends: 10:43:29
Australia Stock Exchange release from EMYRIA : Emyria launches second ultra-pure CBD capsule
Australia Stock Exchange release from EMYRIA : PRE_NR Ends: 10:09:19
Australia Stock Exchange release from EMYRIA : EMD-RX5 program advancing Phase 1 clinical trials underway
Australia Stock Exchange release from EMYRIA : PRE_NR Ends: 09:58:33
Australia Stock Exchange release from EMYRIA : Recruitment commenced for EMD-RX5 Phase 1 Study
Australia Stock Exchange release from EMYRIA : Hidden Gems Webinar Presentation
Australia Stock Exchange release from EMYRIA : Ethics approval received for EMD-RX5 Phase 1 Study
Australia Stock Exchange release from EMYRIA : PRE_NR Ends: 13:52:53
Australia Stock Exchange release from EMYRIA : Emyria to present at Hidden Gems Webinar March 4th